The invention describes and can suppress the compound of phosphatidic acid phosphohydrolase (PAP) and their combination for preparing the purposes of the medicine that can be used for treating cancer; PAP inhibitor can be for blocking the development of other members' that depend on EGF-R ELISA (EGFR) its carcinogenic variant and ErbB family cancer and this is can promote the stimulation of cancer survival and development to carry out by inducing its endocytosis and therefore making them not contact; PAP inhibitor as a part of the present invention comprises such medicine: it is at present for other clinical objects and except being cationic amphiphilic molecule they are incoherent; These comprise Propranolol desipramine and chlorpromazine for the medicine of other clinical objects; The present invention includes all PAP inhibitor comprise sphingol and BEL and any can detectable novel inhibitors in future.

暂无附图